ArticleThe New England journal of medicine2021
Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome".
Abstract read
In one paragraph
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study.JAC-antimicrobial resistance · 2026Article
- Thiazolyl-Methylthio-1,3,4-Thiadiazole Hybrids as Halicin Analogues with Antimicrobial and Antibiofilm Activities: Chemical Development, Biological Assessment, and 2D-QSAR Study.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.Frontiers in cellular and infection microbiology · 2026Article
- Retrospective analysis of adverse drug reaction patterns from the national monitoring system in a tertiary care hospital in China (2019-2024).Open medicine (Warsaw, Poland) · 2026Article
- Reversible Severe Cardiomyopathy Associated With Supratherapeutic Vancomycin Levels: A Case Report.Cureus · 2025Article
- Documentation of DRESS in the allergy list of patients with a prior history of DRESS.The journal of allergy and clinical immunology. In practice · 2025Article
- Rethinking neglected tropical diseases: A shift towards more inclusive and equitable terminology.PLOS global public health · 2025Article
- A Skin Testing Strategy for Non-IgE-Mediated Reactions Associated With Vancomycin.The journal of allergy and clinical immunology. In practice · 2024Article
- A Working Framework to Address Diversity, Equity, and Inclusion in Undergraduate Medical Education.Medical science educator · 2024Article
- Non-IgE-Mediated Immediate Drug-Induced Hypersensitivity Reactions.The journal of allergy and clinical immunology. In practice · 2024Article
- Vancomycin Flushing Syndrome: A Case Report.Cureus · 2024Article
- Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.Children (Basel, Switzerland) · 2024Article
- Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis.Diagnostics (Basel, Switzerland) · 2024Review
- Clinical characteristics and risk factors analysis of 505 cases of infusion reactions in a tertiary hospital.Frontiers in pharmacology · 2024Article
- Ethnopsychopharmacology: Clinical and scientific writing pearls.The mental health clinician · 2023Article
- Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical presentation and outcomes in people of color.The journal of allergy and clinical immunology. In practice · 2023Article
- Vancomycin flushing syndrome in orthopaedic practice: A case report.World journal of orthopedics · 2023Article
- Article
- Limitations of randomised controlled trials as evidence of drug safety.Australian prescriber · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Santiago Alvarez-ArangoFrom the Divisions of Allergy and Clinical Immunology and of Clinical Pharmacology (S.A.A.) and the Department of Medicine (S.M.O.), Johns Hopkins University, and the Johns Hopkins Center for Health Equity (S.M.O.) - both in Baltimore; and the Department of Medicine, Brigham and Women's Hospital (T.D.S.), Harvard Medical School (T.D.S., K.G.B.), and the Division of Rheumatology, Allergy, and Immunology (C.M.B., K.G.B.), and the Edward P. Lawrence Center for Quality and Safety (K.G.B.), Massachusetts General Hospital - all in Boston.ORCID 0000-0002-4110-7221
S Michelle OgunwoleFrom the Divisions of Allergy and Clinical Immunology and of Clinical Pharmacology (S.A.A.) and the Department of Medicine (S.M.O.), Johns Hopkins University, and the Johns Hopkins Center for Health Equity (S.M.O.) - both in Baltimore; and the Department of Medicine, Brigham and Women's Hospital (T.D.S.), Harvard Medical School (T.D.S., K.G.B.), and the Division of Rheumatology, Allergy, and Immunology (C.M.B., K.G.B.), and the Edward P. Lawrence Center for Quality and Safety (K.G.B.), Massachusetts General Hospital - all in Boston.ORCID 0000-0001-9479-7695
Thomas D SequistFrom the Divisions of Allergy and Clinical Immunology and of Clinical Pharmacology (S.A.A.) and the Department of Medicine (S.M.O.), Johns Hopkins University, and the Johns Hopkins Center for Health Equity (S.M.O.) - both in Baltimore; and the Department of Medicine, Brigham and Women's Hospital (T.D.S.), Harvard Medical School (T.D.S., K.G.B.), and the Division of Rheumatology, Allergy, and Immunology (C.M.B., K.G.B.), and the Edward P. Lawrence Center for Quality and Safety (K.G.B.), Massachusetts General Hospital - all in Boston.
Caitlin M BurkFrom the Divisions of Allergy and Clinical Immunology and of Clinical Pharmacology (S.A.A.) and the Department of Medicine (S.M.O.), Johns Hopkins University, and the Johns Hopkins Center for Health Equity (S.M.O.) - both in Baltimore; and the Department of Medicine, Brigham and Women's Hospital (T.D.S.), Harvard Medical School (T.D.S., K.G.B.), and the Division of Rheumatology, Allergy, and Immunology (C.M.B., K.G.B.), and the Edward P. Lawrence Center for Quality and Safety (K.G.B.), Massachusetts General Hospital - all in Boston.
Kimberly G BlumenthalFrom the Divisions of Allergy and Clinical Immunology and of Clinical Pharmacology (S.A.A.) and the Department of Medicine (S.M.O.), Johns Hopkins University, and the Johns Hopkins Center for Health Equity (S.M.O.) - both in Baltimore; and the Department of Medicine, Brigham and Women's Hospital (T.D.S.), Harvard Medical School (T.D.S., K.G.B.), and the Division of Rheumatology, Allergy, and Immunology (C.M.B., K.G.B.), and the Edward P. Lawrence Center for Quality and Safety (K.G.B.), Massachusetts General Hospital - all in Boston.
Funding
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4MThe Clinical and Economic Impact of Penicillin AllergyK01AI125631 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BLUMENTHAL, KIMBERLY GOLD · 2016 to 2021
$779kNIAID NIH HHS K01 AI125631NIGMS NIH HHS T32 GM066691
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug HypersensitivityElectronic Health RecordsTerminology as TopicAnti-Bacterial AgentsEducation, MedicalErythemaFemaleHumansInfusions, IntravenousMaleNatural Language ProcessingRacismSyndromeVancomycinAnti-Bacterial AgentsVancomycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.